- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Achieve Announces Results of Clinical Study Demonstrating Similar Bioavailability of Cytisine in Fed and Fasted Subjects
Achieve Life Science (NASDAQ:ACHV) has announced results of a clinical study evaluating the effect of food on the bioavailability of 3mg cytisine. As quoted in the press release: The study evaluated the bioavailability of 3 mg cytisine under fed and fasted conditions in 24 healthy volunteer subjects. Study results demonstrated bioequivalence when cytisine was administered …
Achieve Life Science (NASDAQ:ACHV) has announced results of a clinical study evaluating the effect of food on the bioavailability of 3mg cytisine.
As quoted in the press release:
The study evaluated the bioavailability of 3 mg cytisine under fed and fasted conditions in 24 healthy volunteer subjects. Study results demonstrated bioequivalence when cytisine was administered with or without food. Cytisine was extensively absorbed after oral administration with maximum cytisine concentration levels observed in the blood within less than an hour. Total excretion levels of cytisine also remained equivalent in both the fed and fasted states. Further data from this study will be submitted for presentation at an upcoming scientific congress.
Additionally, in preparation to initiate a pivotal Phase 3 program in the United States, Achieve recently began enrollment in a multi-dose, pharmacokinetic and pharmacodynamics (PK/PD) clinical study. An assessment of PK parameters and PD effects is planned to be conducted on both the 1.5mg standard and 3.0mg higher-dose of cytisine administered over the currently indicated 25-day scheduled duration of cytisine treatment. The multi-dose PK/PD study is expected to have results within the first-quarter of 2018.
“We are pleased with the rapid completion of this study in fed versus fasted subjects and the findings that a higher dose of 3 mg cytisine can be administered safely with or without food,” said Rick Stewart, Chairman and CEO of Achieve. “The results help to inform our future development plans, including our Phase 3 program which we expect to initiate in mid-2018.”
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.